Isolation of drugs active against mammalian prions using a yeast-based screening assay

Nature Biotechnology

Volumn 21, Issue 9, 2003, Pages 1075-1081

  Bach, Stéphane ^a   Talarek, Nicolas ^b   Andrieu, Thibault ^c   Vierfond, Jean Michel ^d   Mettey, Yvette ^d   Galons, Hervé ^e   Dormont, Dominique ^c   Meijer, Laurent ^a   Cullin, Christophe ^b   Blondel, Marc ^a  

^a STATION BIOLOGIQUE   (France)

^b Institut de Biochimie et Genetique Cellulaires   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d Faculte de Medicine et de Pharmacie   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; DRUG PRODUCTS; YEAST;

ANTIPRION DRUGS;

BIOTECHNOLOGY;

6 AMINO 8 CHLOROPHENANTHRIDINE; 6 AMINO 8 TRIFLUOROMETHYLPHENANTHRIDINE; 6 AMINOPHENANTHRIDINE; ANTIINFECTIVE AGENT; ANTIPRION AGENT; CHLORPROMAZINE; GUANIDINE; KASTELLPAOLITINE; MEPACRINE; PHENANTHRIDINE DERIVATIVE; PRION PROTEIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; BUDDING; CHEMICAL ANALYSIS; CLEARANCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MAMMAL; NONHUMAN; PHENOTYPE; PRION; PRION DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS; YEAST;

ANIMALS; CELL LINE, TUMOR; COLONY COUNT, MICROBIAL; HUMANS; MAMMALS; MICE; NEUROBLASTOMA; PHENANTHRIDINES; PRIONS; PROTEIN INTERACTION MAPPING; SACCHAROMYCES CEREVISIAE; SPECIES SPECIFICITY; YEASTS;

ANIMALIA; MAMMALIA; MAMMALIAN PRIONS; SACCHAROMYCETALES;

EID: 10744225913     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt855     Document Type: Article

References (34)

1. Prusiner, S.B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982).
2. Aguzzi, A., Glatzel, M., Montrasio, F., Prinz, M. & Heppner, F.L. Interventional strategies against prion diseases. Nat. Rev. Neurosci. 2, 745-749 (2001).
3. Wille, H. et al. Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl. Acad. Sci. USA 99, 3563-3568 (2002).
4. Cohen, F.E. et al. Structural clues to prion replication. Science 264, 530-531 (1994).
5. Korth, C., May B.C., Cohen, F.E. & Prusiner, S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA 98, 9836-9841 (2001).
6. Wickner, R.B., Edskes, H.K., Roberts, B.T., Pierce, M. & Baxa, U. Prions of yeast as epigenetic phenomena: high protein "copy number" inducing protein "silencing." Adv. Genet. 46, 485-525 (2002).
7. Cox, B.S. Psi, a cytoplasmic supressor of super-supressor in yeast. Heredity 20, 505-521 (1965).
8. Lacroute, F. Non-Mendelian mutation allowing ureidosuccinic acid uptake in yeast. J. Bacteriol. 106, 519-522 (1971).
9. Wickner, R.B. [URE3] as an altered Ure2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 264, 566-569 (1994).
10. Serio, T.R. & Lindquist, S.L. [PSI+], SUP35, and chaperones. Adv. Protein Chem. 57, 335-366 (2001).
11. Couzin, J. Molecular biology. In yeast, prions' killer image doesn't apply. Science 297, 758-761 (2002).
12. True, H.L. & Lindquist, S.L. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 407, 477-483 (2000).
13. Wegrzyn, R.D., Bapat, K., Newnam, G.P., Zink, A.D. & Chernoff, Y.O. Mechanism of prion loss after Hsp104 inactivation in yeast. Mol. Cell. Biol. 21, 4656-4669 (2001).
14. Eaglestone, S.S., Ruddock, L.W., Cox, B.S. & Tuite, M.F. Guanidine hydrochloride blocks a critical step in the propagation of the prion-like determinant [PSI(+)] of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 97, 240-244 (2000).
15. Ferreira, P.C., Ness, F., Edwards S.R., Cox, B.S. & Tuite, M.F. The elimination of the yeast [PSI+] prion by guanidine hydrochloride is the result of Hsp104 inactivation. Mol. Microbiol, 40, 1357-1369 (2001).
16. Jung, G. & Masison, D.C. Guanidine hydrochloride inhibits Hsp104 activity in vivo: a possible explanation for its effect in curing yeast prions. Curr. Microbiol. 43, 7-10 (2001).
17. Chernoff, Y.O., Lindquist, S.L., Ono, B., Inge-Vechtomov, S.G. & Liebman, S.W. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+]. Science 268, 880-884 (1995).
18. Nishida, N. et al, Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J, Virol. 74, 320-325 (2000).
19. Blondel, M. et al. Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. EMBO J. 19, 6085-6097 (2000).
20. Tuite, M.F., Mundy, C.R. & Cox, B.S. Agents that cause a high frequency of genetic change from [psi+] to [psi-] in Saccharomyces cerevisiae. Genetics 98, 691-711 (1981).
21. Jones, G.W., Song, Y. & Masison, D.C. Deletion of the Hsp70 chaperone gene SSB causes hypersensitivity to guanidine toxicity and curing of the [PSI(+)] prion by increasing guanidine uptake in yeast. Mol. Genet. Genomics 269, 304-311 (2003).
22. Schlumpberger, M., Prusiner, S.B. & Herskowitz, I. Induction of distinct [URE3] yeast prion strains. Mol. Cell. Biol. 21, 7035-7046 (2001).
23. Fernandez-Bellot, E., Guillemet, E. & Cullin, C. The yeast prion [URE3] can be greatly induced by a functional mutated URE2 allele. EMBO J. 19, 3215-3222 (2000).
24. Fernandez-Bellot, E. et al. The [URE3] phenotype: evidence for a soluble prion in yeast. EMBO Rep. 3, 76-81 (2002).
25. Zamora, J.M., Pearce, H.L., & Beck, W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells, Mol. Pharmacol. 33, 454-462 (1988).
26. Haigh, J.C., Mackintosh, C. & Griffin, F. Viral, parasitic and prion diseases of farmed deer and bison. Rev. Sci. Tech. 21, 219-248 (2002).
27. Jarrett, J.T. & Lansbury, P.T., Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058 (1993).
28. Krobitsch, S. & Lindquist, S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. USA 97, 1589-1594 (2000).
29. Osherovich, L.Z. & Weissman, J.S. Multiple Gln/Asn-rich prion domains confer susceptibility to induction of the yeast [PSI(+)] prion. Cell 106, 183-194 (2001).
30. Meriin, A.B. et al. Huntingtin toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J. Cell Biol. 157, 997-1004 (2002).
31. Caughey, B. & Race, R.E. Potent inhibition of scrapie-associated PrP accumulation by congo red. J. Neurochem. 59, 768-771 (1992).
32. Supattapone, S., Nguyen, H.O., Cohen, F.E., Prusiner, S.B. & Scott, M.R, Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. USA 96, 14529-14534 (1999).
33. Guthrie, C. & Fink, G.R. Guide to Yeast Genetics and Molecular Biology, 194 (Academic Press, San Diego, California, 1991).
34. Baudin, A., Ozier-Kalogeropoulos, O., Denouel, A., Lacroute, F. & Cullin, C. A simple and efficient method for direct gene deletion in Saccharomyces cerevisiae. Nucleic Acids Res. 21, 3329-3330 (1993).